Hemab Therapeutics Holdings, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Novo Holdings A/S has reported beneficial ownership of 9.0% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.
NASDAQ
Avoro Capital Advisors, Avoro Ventures, and Behzad Aghazadeh have collectively reported beneficial ownership of 7.06% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.
NASDAQ
Capital International Investors has disclosed beneficial ownership of 3,603,876 shares, representing 7.7% of Hemab Therapeutics Holdings, Inc.'s common stock.
NASDAQ
Several entities affiliated with Invus Group and Raymond Debbane have reported beneficial ownership of Hemab Therapeutics Holdings, Inc. common stock, collectively holding 5.1% of the outstanding shares.
NASDAQ
Sofinnova Crossover II SLP and associated entities have reported beneficial ownership of 5.4% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.